Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference.
Huang D., Tee WW., De Mel S., Itahana K., Sabapathy K., Ramadan K., Taneja R., Le Minh G., Ong DST., Yeow ZY., Ong ST., Zhou Y., Khong A., Lee S-C., Lucky SS., Tam WL., Iyer NG., Ong CK.
The 17th Annual Frontiers in Cancer Science (FCS) conference (2025) highlighted the convergence of multiomics, computational biology, and ancestry-specific genomics to advance proactive cancer care. Key insights included the role of epigenetic plasticity in maintaining tumor-propagating states and the identification of metabolic vulnerabilities, such as the WNK1-mTORC1 axis in leukemia and MAF-driven glutamine metabolism in myeloma. The meeting underscored the systemic nature of cancer, detailing how "cancer-educated" neutrophils prime premetastatic niches and how spatial exclusion mechanisms hinder immunotherapy. Breakthroughs in therapeutic engineering were showcased, including CD7-directed chimeric antigen receptor T cells and irreversible KRASG12C inhibitors. A critical focus remained on precision oncology for diverse populations, advocating for ancestry-aware datasets and long-read sequencing to address genomic disparities in Asian cohorts. Furthermore, the integration of artificial intelligence-driven "fragmentomics" and machine learning offers new pathways for early detection and tracking disease lethality. Collectively, FCS 2025 demonstrated that the future of oncology lies in integrating high-resolution disease models with robust data science to transition from reactive treatment to personalized, interceptive management.